Phaseline

Companies › Aclaris Therapeutics

Aclaris Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ATI-045–Phase 2Atopic DermatitisNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07011706ATI-045Phase 2Atopic DermatitisImmunologyNov 2026

From the company's SEC filings

Cash and short-term investments of $205m on 2026-09-30; operating cash outflow about $83m a year; runway about 30 months at that burn, to Mar 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Palisade Bio Quoin Pharmaceuticals Toll Biotech Co. Ltd. (Beijing) Ventus Therapeutics U.S. Navigator Medicines

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.